Detalles de la búsqueda
1.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res
; 26(1): 36, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38439079
2.
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung Cancer
; 189: 107451, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38354535
3.
Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease.
Front Digit Health
; 5: 1099456, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37426890
4.
Unsupervised machine-learning algorithms for the identification of clinical phenotypes in the osteoarthritis initiative database.
Semin Arthritis Rheum
; 58: 152140, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36446256
5.
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Target Oncol
; 18(6): 853-868, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875771
6.
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
CPT Pharmacometrics Syst Pharmacol
; 11(8): 1122-1134, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728123
7.
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).
Clin Pharmacol Ther
; 112(6): 1329-1339, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131557
8.
Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
BJU Int
; 104(6): 813-7; discussion 817-8, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19254280
9.
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
JAMA Oncol
; 5(2): e184475, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30543347
10.
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
JAMA Oncol
; 4(10): 1335-1343, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29902286
11.
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
J Clin Oncol
; 36(13): 1291-1299, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29401002
12.
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Cancer Chemother Pharmacol
; 82(2): 285-298, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29882016
13.
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Clin Cancer Res
; 21(4): 730-8, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25500057
14.
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
J Clin Oncol
; 30(3): 282-90, 2012 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22162589
Resultados
1 -
14
de 14
1
Próxima >
>>